A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer. 1990

D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
Department of Urology, West Virginia University Health Sciences Center, Morgantown.

Reports of a dramatic decrease in tumor recurrence and regression of muscle invasive disease with oral bacillus Calmette-Guerin prompted us to conduct a randomized prospective comparison of oral bacillus Calmette-Guerin with the standard intravesical plus percutaneous therapy. Oral therapy consisted of 200 mg. Tice bacillus Calmette-Guerin 3 times each week. Intravesical and percutaneous Tice bacillus Calmette-Guerin at a dose of 50 mg. was given weekly for 6 weeks, at 8, 10 and 12 weeks, then at 6 months and every 6 months thereafter. Minimal side effects confirmed the safety of oral bacillus Calmette-Guerin. Tumor recurrence was documented in 21 of 33 oral bacillus Calmette-Guerin patients (64%) and 18 of 55 (33%) who received intravesical plus percutaneous therapy (p less than 0.002, chi-square test). We were unable to demonstrate any antitumor activity of oral bacillus Calmette-Guerin in this study.

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000283 Administration, Intravesical The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. Bladder Drug Administration,Drug Administration, Bladder,Instillation, Bladder,Intravesical Drug Administration,Administration, Intravesical Drug,Injections, Intravesical,Intravesical Administration,Intravesical Injection,Intravesical Instillation,Administration, Bladder Drug,Administrations, Bladder Drug,Administrations, Intravesical,Administrations, Intravesical Drug,Bladder Drug Administrations,Bladder Instillation,Bladder Instillations,Drug Administration, Intravesical,Drug Administrations, Bladder,Drug Administrations, Intravesical,Injection, Intravesical,Instillation, Intravesical,Instillations, Bladder,Instillations, Intravesical,Intravesical Administrations,Intravesical Drug Administrations,Intravesical Injections,Intravesical Instillations

Related Publications

D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
October 1991, Archivos espanoles de urologia,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
July 1994, Hinyokika kiyo. Acta urologica Japonica,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
August 1999, The Journal of urology,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
February 1996, The Journal of urology,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
July 1985, The Journal of urology,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
July 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
February 1991, Urology,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
June 2003, Urologic nursing,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
September 1989, The Journal of urology,
D L Lamm, and J I DeHaven, and J Shriver, and R Crispen, and D Grau, and M F Sarosdy
January 2000, Asian Pacific journal of cancer prevention : APJCP,
Copied contents to your clipboard!